Biblio
Export 3921 results:
Author Title Type Year Filters: First Letter Of Last Name is F [Clear All Filters]
“Interactions between Atrial Fibrillation, Cardiovascular Risk Factors, and ApoE Genotype in Promoting Cognitive Decline in Patients with Alzheimer's Disease: A Prospective Cohort Study.”, J Alzheimers Dis, vol. 62, no. 2, pp. 713-725, 2018.
, “Oculodentodigital dysplasia with massive brain calcification and a new mutation of GJA1 gene.”, J Alzheimers Dis, vol. 49, no. 1, pp. 27-30, 2016.
, “LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 645-57, 2016.
, “Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.”, J Alzheimers Dis, vol. 64, no. s1, pp. S47-S105, 2018.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Cognitive Stimulation Modulates Platelet Total Phospholipases A2 Activity in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 957-62, 2016.
, “Cognitive Stimulation Modulates Platelet Total Phospholipases A2 Activity in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 957-62, 2016.
, “Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults.”, J Alzheimers Dis, vol. 51, no. 3, pp. 713-25, 2016.
, “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
, “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
, “Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1237-47, 2016.
, “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
, “New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. s1, pp. S51-S63, 2021.
, “Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).”, J Alzheimers Dis, vol. 101, no. 1, pp. 353-367, 2024.
, “Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.”, J Alzheimers Dis, vol. 76, no. 2, pp. 481-489, 2020.
, “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
, “Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity.”, J Alzheimers Dis, vol. 51, no. 1, pp. 165-78, 2016.
, “Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1227-41, 2016.
, “Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1227-41, 2016.
, “Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1235-1247, 2017.
,